Summary by Futu AI
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 11 to April 29, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of Class A during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. This share repurchase was conducted in accordance with the Listing Rules of the Hong Kong Stock Exchange Limited and the relevant rules of the Shanghai Stock Exchange. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.